Evidence & regulatory context
- Mechanism
- Histamine: H1 receptor agonist (AGONIST); study also uses H1 antagonist pyrilamine and H2 antagonist cimetidine
- Target
- CHEMBL231
- Injury models
- Other
- Reported indication
- Not recorded
- First approval
- 1939
- Development stage
- Not recorded
- ChEMBL max phase
- 4 / 4 (development scale, not regulatory approval)
- Synonyms
- Histamine; pyrilamine (co-listed); cimetidine (co-listed)
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseOtherHDC-EGFP BAC transgenic and HDC knockout mice on Balb/C and C57BL/6 backgrounds; H9c2 rat cardiomyoblasts used in vitron = 7 mice in the combined pyrilamine plus cimetidine group; 14…Intraperitoneal in vivo; culture medium in vitroHistamine 4 mg/kg/day intraperitoneally; pyrilamine 10 mg/k…Dosing started 3 days before coronary ligation and continued until euthanasia
Model: Acute myocardial infarction induced by permanent ligation of the left anterior descending coronary artery under isoflurane anaesthesia, with sham thoracotomy controls
Histamine deficiency raised CK-MB, enlarged infarct size, lowered ejection fraction and increased cardiomyocyte apoptosis while reducing early macrophage infiltration, and exogenous histamine reversed these changes; combined pyrilamine plus cimetidine markedly reduced 7 day survival (1 of 7 mice su…
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.